Efficacy and Safety of Low-Dose Intravesical OnabotulinumtoxinA Injections in Female Patients With Detrusor Overactivity With Detrusor Underactivity

Article information

Int Neurourol J. 2024;28(1):52-58

Publication date (electronic) : 2024 March 31

doi : https://doi.org/10.5213/inj.2346228.114

Hyun Seok Na^1,*, Chung Lyul Lee^1,*, Jae Sung Lim¹, Ki Hak Song¹, Ju Hyun Shin¹, Jong Mok Park², Ji Yong Lee^,1

¹Department of Urology, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea

²Department of Urology, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, Korea

Corresponding author: Ji Yong Lee Department of Urology, Chungnam National University College of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea Email: urodragon@naver.com

*Hyun Seok Na and Chung Lyul Lee contributed equally to this study as co-first authors.

Received 2023 September 24; Accepted 2023 December 27.

Abstract

INTRODUCTION

Overactive bladder (OAB) is a common condition characterized by urgency, with or without urinary incontinence, increased daytime frequency, and nocturia [1]. Underactive bladder (UAB) is a symptom complex suggestive of detrusor underactivity (DU), resulting in prolonged or incomplete bladder emptying [1]. Detrusor overactivity with DU (DODU) is a condition in which the bladder is both overactive and underactive, resulting in storage symptoms, such as urgency urinary incontinence (UUI) and voiding difficulties [2]. DODU is a common cause of urinary incontinence in elderly patients and must be diagnosed to avoid unnecessary interventional management.

There is no defined treatment algorithm for patients with DODU; however, they are typically treated based on symptom severity [3]. Treatments for patients with voiding symptoms include alpha-blockers or clean intermittent catheterization (CIC); sacral nerve stimulation may also be considered. For patients with storage symptoms, the first-line treatment is behavioral therapy, such as fluid intake restriction, timed voiding, and Kegel exercises. When behavioral therapy is insufficient, oral medications, including antimuscarinic agents or beta-3 adrenoreceptor agonists are the primary second-line treatment. Highly resistant storage symptoms refractory to oral medications are treated with an intravesical injection of onabotulinumtoxinA (onabotA; BOTOX, Allergan plc, Dublin, Ireland) as an effective third-line treatment [4,5]. Complications of intravesical injection of onabotA include increased postvoid residual (PVR) volume, acute urinary retention (AUR), and risk of urinary tract infection (UTI) [6]. These complications can result in poor patient compliance. Thus, appropriate patient selection is crucial, and patients who are willing to undergo PVR evaluation and CIC are appropriate candidates.

Intravesical onabotA injections can also be used to treat storage symptoms in patients with DODU; however, only one clinical study has been conducted on this topic to date [7]. We conducted our research to assess the effectiveness and safety of intravesical onabotA injection at a low dose of 75 units (U) for treating storage symptoms in patients with DODU compared to the standard 100 U of onabotA in patients with OAB.

MATERIALS AND METHODS

RESULTS

Patient Characteristics

In total, 121 patients who received intravesical onabotA injections were selected. Of these, 87 had OAB, and 34 had DODU. All the enrolled patients were female and aged between 20 and 80 years. The mean age±standard deviation of the DODU and OAB patients were 69.0±11.4 years and 59.5±11.1 years, respectively. There were statistical differences in age and presence of diabetes mellitus (DM) between the 2 groups. No significant differences in other demographic data were observed between the 2 groups (Table 1).

Table 1.

Patient demographics and baseline characteristics

Efficacy Assessment

In the DODU group, all questionnaire scores demonstrated more dramatic and statistically significant improvements in the postoperative ≤2-week period compared to the OAB group (Table 2). In the postoperative ≥12-week period, there was a subsequent decline from the initial improvement; however, an overall trend of improvement compared to baseline was observed. Notably, the DODU group showed an improvement in the IPSS voiding score after onabotA treatment. In the OAB group, most questionnaire scores, excluding the IPSS voiding score, showed significant improvement after onabotA treatment, and this effect persisted to some extent in the postoperative ≥12-week period. The P-values derived from the linear mixed model between the DODU and OAB groups for IPSS voiding and total scores were 0.016 and 0.021, respectively.

Table 2.

Comparison of questionnaire scores at baseline, postoperative≤2 weeks, and postoperative≥12 weeks

Time-course changes in the voiding diary parameters are presented in Table 3. Both urgency and UUI showed substantial improvements in the postoperative ≤2-week period in both groups, with relatively modest effects in the postoperative ≥12-week period (P=0.936 and P=0.460, respectively). While the frequency, daytime frequency, and nocturia parameters also improved in both groups, there was a prominent increase in the average voided volume (AVV) in the DODU group compared to that in the OAB group (P=0.489). The maximum voided volume (MVV) also showed improvement in the DODU group, whereas no improvement was observed in the OAB group (P=0.357).

Table 3.

Comparison of voiding diaries at baseline, postoperative≤2 weeks, and postoperative≥12 weeks

As shown in Table 4, the Qmax and mean flow rate values decreased in the OAB group after onabotA treatment, whereas the DODU group exhibited increased values, with a more pronounced effect observed during the postoperative ≤2-week period. P-values derived by the linear mixed model between the DODU and OAB groups for Qmax and mean flow rate were 0.000. The increase in the voided volume (VV) was more prominent in the DODU group than in the OAB group (P=0.104). The PVR volume increased in both groups posttreatment, with a mitigated rate of change in the postoperative ≥12-week period (P=0.132).

Table 4.

Comparison of uroflowmetries at baseline, postoperative≤2 weeks, and postoperative≥12 weeks

Safety Assessment

Postoperative complications after onabotA treatment are presented in Table 5. AUR occurred in one patient in each group, and both cases were managed with CIC (P=0.487). A high PVR exceeding 200 mL was more prevalent in the OAB group than in the DODU group, although the difference was not statistically significant (17.2% vs. 8.8%, respectively; P=0.242). Dysuria and a weak stream were reported by patients with OAB (10.3% and 5.7%, respectively), but not by patients with DODU. The frequencies of other adverse events were comparable between the groups.

Table 5.

Scale of postoperative complications after intravesical onabotulinumtoxinA injection

DISCUSSION

DU is characterized by reduced strength and/or duration of bladder contractions, resulting in prolonged bladder emptying or failure to achieve complete bladder emptying within a normal period, as defined by the International Continence Society [13]. However, the definitions of “prolonged bladder emptying” and “normal period” lack clarity, leading to varying definition interpretations of DODU in clinical studies [8-10]. Wang et al. [7] defined DODU as a baseline PVR volume of >100 mL but <250 mL or a BVE of <67% in patients with OAB. Despite this inconsistency, a comprehensive urodynamic database study utilized a stringent definition based on EAU expert opinions [11]; women with DU were defined as those with PdetQmax <20 cm H₂O, Qmax <15 mL/sec, BVE <90%, and no sign of obstruction in video-urodynamic studies. Our study adhered to these criteria when selecting patients for DODU.

Intravesical onabotA 100 U is the standard dose for treating refractory idiopathic OAB in adults of both sexes and is licensed in Europe [14,15]. However, elderly and fragile patients with OAB may experience advantages from a lower dosage of onabotA owing to alterations in bladder physiology associated with aging, increased usage of medications affecting detrusor function, and a reciprocal connection with additional geriatric conditions such as frailty, rendering a lower dosage more suitable for them [16].

Despite numerous studies investigating the appropriate dosage for onabotA treatment in OAB [14-16], there is a lack of established optimal dosages for onabotA in DODU treatment, and limited clinical investigations of its efficacy and safety. To address this gap, our study explored the use of a lower dosage, specifically 75 U, for treating DODU, considering the potential exacerbation of voiding symptoms after Botox therapy due to concurrent voiding impairment in these patients. The results indicated a shorter duration of treatment compared to OAB, yet a notable improvement in the storage symptoms of DODU was achieved without significant complications. This improvement was observed not only in subjective surveys but also in voiding diaries, where parameters related to storage symptoms showed enhancement.

The efficacy of the onabotA therapy established for OAB is hypothesized to apply to DODU because of its shared pathophysiological characteristics. Morphological analysis of bladder biopsies from patients with DODU has demonstrated characteristics of both detrusor overactivity (dysjunctional pattern) and impaired detrusor contractility typically observed in aging bladders (neural degeneration, interstitial fibrosis, and dense band pattern in smooth muscle cells) [2,17]. The hypothesis that chronically untreated or treatment-refractory OAB can progress over time to DODU and subsequently to UAB provides further support [18]. Therefore, the mechanism of action of onabotA may also apply to DODU. OnabotA inhibits the release of neurotransmitters such as acetylcholine and adenosine triphosphate at presynaptic cholinergic junctions, restrains detrusor contraction, and augments bladder capacity [19,20].

A noteworthy observation in our study was the improvement in the IPSS voiding score, Qmax, and mean flow rate following onabotA treatment for DODU. This trend suggests that the onabotA effect of reducing bladder sensitivity and increasing bladder capacity leads to larger VVs, thereby potentially affecting voiding symptoms and flow rate. Consequently, the increase in VV, AVV, and MVV after onabotA treatment was more pronounced in the DODU group compared to the OAB group, as observed in this study. This finding is consistent with that of a previous investigation of mirabegron in female patients with OAB. Matsukawa et al. reported that mirabegron not only improved storage function but also increased voiding function parameters, such as Qmax and PdetQmax [21].

Conversely, our observations differ from a previous study by Wang et al. [7], the only clinical study reporting the impact of intravesical onabotA injection in patients with DODU to date, in which Qmax decreased after treatment in patients with DODU. Wang et al. [7] reported that, although 100 U of intravesical onabotA injection improved subjective urgency symptoms without increasing the risk of adverse events in patients with DODU, voiding diary parameters, such as the number of urgency episodes, frequency, or UUI, and uroflowmetry parameters did not show improvement after treatment. This discrepancy could be attributed to differences in the diagnostic criteria for DODU and variations in the onabotA dosage.

Limitations of this study include its ambidirectional design, potential bias, and limited generalizability. Although there were no significant differences in other demographic data, the higher mean age and increased prevalence of DM in the DODU group than in the OAB group were recognized as limitations. We employed a general linear model to test the study results and mitigate the potential confounding effects of age and diabetes prevalence. Most parameters did not show a statistically significant relationship, except for OABSS and diabetes prevalence, which had a P-value of 0.010, and Qmax and age, which had a P-value of 0.045. Consequently, the 2 groups can be considered homogeneous, except for the inherent characteristics of the diseases, making it meaningful to compare the effects of intravesical onabotA injections in each group. In addition, the relatively small sample size emphasizes the need for larger studies to corroborate these findings. A randomized dose-ranging trial to compare different doses of onabotA in patients with DODU should be conducted in future studies.

To the best of our knowledge, this is the first study to report the efficacy and safety of low-dose intravesical onabotA treatment for DODU. Low-dose intravesical onabotA treatment for DODU demonstrated a relatively shorter duration of efficacy than that for OAB. Nonetheless, the treatment improved both storage and voiding symptoms in patients with DODU without significant adverse effects. These findings highlighted the potential of onabotA as a treatment option for patients with DODU.

Article information Continued